To address these questions, we analyzed tumor sequencing data generated within the context of a prospective, institution scale genomic profiling initiative to define the landscape of HER2 alterations in bladder and upper tract urothelial cancers, and their association with patient demographic and pathologic features. Here, ERBB2 is linked to neoplasm.